Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study

F. Picard,1 D. Bruel,2 D. Servent,3 W. Saba,2 C. Fruchart-Gaillard,3 M.-A. Schöllhorn-Peyronneau,2 D. Roumenov,2 E. Brodtkorb,4 S. Zuberi,5 A. Gambardella,6 B. Steinborn,7 A. Hufnagel,8 H. Valette2 and M. Bottlaender2

1Department of Neurology, University Hospital and Medical School of Geneva, Switzerland, 2CEA, Service Hospitalier Frédéric Joliot, DRM/DSV, Orsay, 3CEA, Département d’Ingénierie et d’Études des Protéines, Saclay, France, 4St Olav’s Hospital, Trondheim University Hospital Trondheim, Norway, 5Royal Hospital for Sick Children, Yorkhill, Glasgow, UK, 6University Magna Graecia, Catanzaro, Italy, 7University of Medical Sciences, Poznan, Poland and 8Department of Neurology, University of Essen, Essen, Germany

Correspondence to: Dr Fabienne Picard, Department of Neurology, University Hospital of Geneva, 24 rue Micheli-du-Crest, 1211 Geneva 14, Switzerland
E-mail: Fabienne.Picard1@hcuge.ch

Nicotinic acetylcholine receptors (nAChRs) are involved in a familial form of frontal lobe epilepsy, autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). In several ADNFLE families, mutations were identified in the nAChR α4 or β2 subunit, which together compose the main cerebral nAChR. Electrophysiological assessment using in vitro expression systems indicated a gain of function of the mutant receptors. However the precise mechanisms by which they contribute to the pathogenesis of a focal epilepsy remain obscure, especially since α4β2 nAChRs are known to be widely distributed within the entire brain. PET study using [18F]-F-A-85380, a high affinity agonist at the α4β2 nAChRs, allows the determination of the regional distribution and density of the nAChRs in healthy volunteers and in ADNFLE patients, thus offering a unique opportunity to investigate some in vivo consequences of the molecular defect. We have assessed nAChR distribution in eight non-smoking ADNFLE patients (from five families) bearing an identified mutation in nAChRs and in seven age-matched non-smoking healthy volunteers using PET and [18F]-F-A-85380. Parametric images of volume of distribution (Vd) were generated as the ratio of tissue to plasma radioactivities. The images showed a clear difference in the pattern of the nAChR density in the brains of the patients compared to the healthy volunteers. Vd values revealed a significant increase (between 12 and 21%, P < 0.05) in the ADNFLE patients in the mesencephalon, the pons and the cerebellum when compared to control subjects. Statistical parametric mapping (SPM) was then used to better analyse subtle regional differences. This analysis confirmed clear regional differences between patients and controls: patients had increased nAChR density in the epithalamus, ventral mesencephalon and cerebellum, but decreased nAChR density in the right dorsolateral prefrontal region. In five patients who underwent an additional [18F]-fluorodeoxyglucose (FDG) PET experiment, hypometabolism was observed in the neighbouring area of the right orbitofrontal cortex. The demonstration of a regional nAChR density decrease in the prefrontal cortex, despite the known distribution of these receptors throughout the cerebral cortex, is consistent with a focal epilepsy involving the frontal lobe. We also propose that the nAChR density increase in mesencephalon is involved in the pathophysiology of ADNFLE through the role of brainstem ascending cholinergic systems in arousal.

Keywords: ADNFLE; genetics; nicotinic receptor; PET; fluoro-A-85380

Abbreviations: ACh = acetylcholine; ADNFLE = autosomal dominant nocturnal frontal lobe epilepsy; CHRNA4 = gene coding for the neuronal nicotinic acetylcholine receptor α4 subunit; CHRNβ2 = gene coding for the neuronal nicotinic acetylcholine receptor β2 subunit; F-A-85380 = 2-fluoro-A-85380; FDG = fluorodeoxyglucose; IPN = interpeduncular nucleus; LDT = laterodorsal tegmental nucleus; nAChR = nicotinic acetylcholine receptor; SPM = statistical parametric mapping; Vd = volume of distribution; VOI = volume of interest

**Introduction**

Nocturnal frontal lobe epilepsy (NFLE) is a common non-lesional focal epilepsy (Provini et al., 1999). It is sometimes familial, with an autosomal dominant mode of inheritance (Scheffer et al., 1995). More than a hundred families with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) have been reported since the description of the familial form (Picard and Scheffer, 2005). A more definitive answer might be obtained with studies of receptor distribution in the living human brain. In vivo PET studies may help to understand the link between the molecular alteration, the cellular dysfunction and the clinical expression.

ADNFLE was the first idiopathic epilepsy in which a causative gene was found. Mutations were identified in twelve families and in one sporadic case in the CHRNA4 and the CHRNA2 genes coding for two different subunits (α4 and β2) of the neuronal nicotinic acetylcholine receptor (nAChR) (Steinlein et al., 1995; Phillips et al., 2000; Bertrand et al., 2002; Picard and Scheffer, 2005). This finding opened the new era of epilepsies considered as channelopathies. However, the discovery of a responsible gene does not imply a prompt understanding of the pathogenesis of the disease. The nAChR α4 and β2 subunits are known to assemble, classically in a 2α/3β ratio, and to form the main brain nicotinic receptor subtype in humans. All identified ADNFLE mutations are located within the M2 or M3 transmembrane segments lining the ionic pore of the receptor. The mutant nAChRs have been electrophysiologically studied in vitro. In order to mimic the in vivo conditions of an autosomal dominant disease, co-injection in frog oocytes of both the normal and mutant alleles of the mutant gene, in addition to the normal allele of the other subunit, resulted in expression of ‘heterozygous’ mutant receptors. In these conditions, the only common electrophysiological finding for six studied mutations was a significant increase in sensitivity to acetylcholine (ACh) of the mutant receptors (Moulard et al., 2001; Phillips et al., 2000; Bertrand et al., 2002, 2005; Leniger et al., 2003). Another mutation, the CHRNA2 V287L mutation, caused a retardation of channel desensitization (De Fusco et al., 2000). Thus, contrary to the first conclusions deduced from the assessment of ‘homozygous’ mutant receptors (Weiland et al., 1996), the recent studies suggest a gain of function of the mutant nicotinic receptors. As an alternative common mechanism, another study of five mutations suggested a reduction of the Ca2+ dependence of the ACh response (Rodrigues-Pinguet et al., 2003).

Although the electrophysiological studies suggest that a gain of function of the mutant receptors may exist in vivo, the precise mechanisms behind the epilepsy in ADNFLE remain unknown. The α4β2 nAChRs are widely distributed, in particular in the thalamus and the cortex, yet their precise distribution in the human brain is still incompletely known. Most of these receptors are presynaptic and have a neuro-modulatory role consisting of an enhancement of the release of GABA, glutamate, dopamine, norepinephrine, serotonin or ACh. Some receptors that alter the release of various neurotransmitters are axonal at a preterminal location (Lena et al., 1993). The presence of postsynaptic receptors has also been demonstrated; they mediate fast excitatory synaptic transmission (Dani, 2001). Until now, the brain and cellular (pre-, post- or extrasynaptic) localizations of the mutant α4β2 nAChRs directly involved in ADNFLE pathogenesis have not been identified. Although animal models might provide a first insight into the pathogenesis, their results must be interpreted with caution given the differences in brain organization and receptor distribution.

**Material and methods**

**In vitro studies**

**Materials**

cDNA coding for human α4, β2 and α4–S248F were kindly provided by O. Steinlein (University of Munich, School of Medicine, Institute of Human Genetics, Munich, Germany) and β2–V287L by G. Casari (San Raffaele University, Milan, Italy). (.±)-[3H]epibatidine (55.3 Ci/mmoll was purchased from PerkinElmer and carbamazepine from Sigma. cDNA coding for neuronal nicotinic receptor subunits (wild-type and mutant α4 and β2) were transfected into human embryonal kidney (HEK 293) cells by calcium precipitation as described previously (Chen and Okayama, 1987). Briefly, for the wild-type receptor, cDNAs (7 μg α4 + 7 μg β2) were transfected by calcium precipitation with careful control of the pH (6.95). For the mutant receptors, different types of transfection were made in order to simulate a ‘heterozygous’ (3.5 μg α4 + 3.5 μg α4-S248F + 7 μg β2) or (7 μg α4 + 3.5 μg β2 + 3.5 μg β2-V287L) or a ‘homozygous’ (7 μg α4-S248F + 7 μg β2) or (7 μg α4 + 7 μg β2-V287L) mutant receptor. The cells were placed at 37°C under 5% CO2 and 20 h after transfection the medium was changed. Then, the cells were placed for 2 days at 30°C, under 5% CO2 before collection in a phosphate-buffered saline (PBS) with 5 mM EDTA, washed twice with PBS and finally resuspended in 3 ml/plate of this buffer for the binding experiments.
**Competition binding assays**
The affinities of epibatidine and F-A-85380 for the different α4β2 constructions were determined by equilibrium binding experiments using [3H]-epibatidine as radioactive tracer. Cells expressing the receptor were incubated with 0.5 nM [3H]-epibatidine and various concentrations of competitive ligands for 2 h. The solution was filtered through GF/C filters, previously soaked in PBS + polyethylenimine 0.5%, and the filters were washed with 6 ml of cold PBS, dried and counted on a Rackbeta counter (PerkinElmer LAS, Courtaboeuf, France) after the addition of 10 ml of scintillation solution (Lipoluma-PerkinElmer LAS, Courtaboeuf, France).

In equilibrium competition experiments, IC50 values were determined by fitting the competition data by the empirical Hill equation and converted to Ki constants using the Cheng–Prusoff equation with Kd value [3H]-epibatidine on human α4β2 of 20 pM.

All experiments were performed at least three times in duplicate to ensure consistency.

Almost all the patients (6/8) were treated with carbamazepine at the time of the study. This drug seems to act on the ionic pore of the nAChRs as an open channel blocker (Picard et al., 1999). An additional effect on the binding site has never been excluded. Therefore, the effect of carbamazepine on the F-A-85380/[3H]-epibatidine binding on both wild-type and mutant receptors was evaluated by measuring the potency of 50 μM of carbamazepine to compete with the radiotracer and by comparing the Ki of F-A-85380 with or without 50 μM of carbamazepine. This concentration is within the presumed therapeutic range (20–50 μM).

**Saturation binding assays using [18F]-F-A-85380**
Assays were carried out at 37°C in HEPES-salt solution (HSS), containing HEPES (pH 7.4, 15 mM), 120 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl2 and 1.8 mM CaCl2. Cells expressing the receptor (10 μl) were incubated for 2 h in a total volume of 2 ml with 0.04 to 33 nM [18F]-F-A-85380. Non-specific binding was determined in the presence of 300 μM (-)-nicotine. Incubation was terminated by filtration through GF/B glass fibre filters, presoaked in 1% polyethylenimine, using a Brandel 48-channel cell harvester (Inotech-HI-110, PerkinElmer, Courtaboeuf, France). Filters were washed three times with 3 ml aliquots of buffer [50 mM Tris–HCl (pH 7.4)]. Radioactivity was measured using an automatic gamma counter (model 5000; Packard Instrument Co., Downers Grove, IL). Binding parameters were determined from experimental data using a non-linear least squares regression program (GraphPad Prism). All experiments were performed at least three times in triplicate.

**In vivo studies**

**Subjects**

Eight non-smoking Caucasian patients with ADNFLE and an identified mutation in the nicotinic receptor (seven men; one woman; mean age = 31 years, SD = 13.2) and seven non-smoking age-matched healthy Caucasian volunteers (seven men; mean age = 35 years, SD = 15.5; P = 0.44) were studied. All patients were right-handed.

These patients belong to five families previously reported to harbour mutations in the CHRNA4 (nAChR α4 subunit) gene or the CHRNA2 (nAChR β2 subunit) gene. The patients came from Scotland [Family D (McLellan et al., 2003)], Norway (Steinlein et al., 2000), Italy (De Fusco et al., 2000; Gambardella et al., 2000), Poland (Rozycka et al., 2003) and Germany (Leniger et al., 2003). Six patients had mutations in the α4 subunit and two in the β2 subunit. Patient characteristics, including type of mutation, are shown in Table 1.

The usual antiepileptic medication was continued at the time of the PET examination. Three patients were on carbamazepine alone, three patients on carbamazepine plus clonazepam or clobazam (of whom one demonstrated non-compliance with an undetectable plasma level of carbamazepine, <2.5 μg/ml), one patient on oxcarbazepine plus levetiracetam and one on clobazam alone.

Two patients had seizures the night before the [18F]-F-A-85380 PET examination.

**Study design**

The study protocol for this investigation was approved by the Medical Bioethics Committee of the Medical Centre at the University of Paris XI and written informed consent was obtained from all subjects.

All subjects had a MRI scan and a [18F]-F-A-85380 PET scan on the same day. Neither patients nor controls fell asleep during the PET examination. In addition, five of the patients had a [18F]-fluorodeoxyglucose (FDG) PET on the following day. All PET studies were performed using an ECAT EXACT HR+ tomograph (Siemens Medical Solutions, Knoxville, TN, USA). This tomograph allows simultaneous acquisition in 3D mode of 63 slices with an isotropic intrinsic resolution of 4.5 mm.

**Magnetic resonance imaging**

MRI scan was performed on a 1.5 tesla signa system (General Electric, Milwaukee, WI). A T1-weighted inversion-recovery sequence in 3D mode and a 256 × 192 matrix over 124 slices (1.5 mm thick) were used to generate the anatomical images.

**[18F]-F-A-85380 PET imaging**

A-85380 was labelled with fluorine-18 by no-carrier-added nucleophilic aromatic substitution (Doll et al., 1999). [18F]-F-A-85380 (188 ± 24 MBq, 2–3 nmol) was injected intravenously. The PET acquisition started 3 h later and lasted 1 h. In five control subjects, the PET acquisition started immediately after tracer injection and lasted 240 min with a rest period between 150 and 210 min (Gallezot et al., 2005). A thermobile plastic face mask ensured a stable position of the head. Attenuation correction was performed in each individual after segmentation of the attenuation map, using a 60Ge transmission scan acquired for 15 min. Venous plasma samples were drawn and unchanged radiotracer fraction was measured in the plasma using solid phase extraction. Briefly, a 500 μl plasma sample was acidified, directly applied onto a 30 mg Oasis MCX-SPE column and washed with 0.1 N HCl, MeOH and MeOH/H2O/NH4OH 50/48/2 (v/v). [18F]-F-A-85380 was eluted twice with a MeOH/NH4OH 95/5 (v/v) solution. The radioactivity due to unchanged [18F]-F-A-85380 in the eluted fractions was measured in a gamma counter (Cobra Quantum D5033, PerkinElmer, Courtaboeuf, France) (Schollhorn–Peyronneau et al., 2005).

**[18F]-FDG PET imaging**

[18F]-FDG was injected intravenously at a mean dose of 148 MBq. Image acquisition started with the injection and lasted...
<table>
<thead>
<tr>
<th>Country, patient no.</th>
<th>Mutation</th>
<th>Sex</th>
<th>Age, years</th>
<th>Age at onset, years</th>
<th>Ictal symptoms</th>
<th>Ictal breathing difficulty</th>
<th>Loss of consciousness</th>
<th>Duration of attacks</th>
<th>Secondary generalization</th>
<th>Postictal phenomena</th>
<th>Time of attacks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norway IV-6 (Steinlein et al., 2000)</td>
<td>α4-S248F</td>
<td>M</td>
<td>45</td>
<td>13</td>
<td>Strange feeling in head, hyperpnoea, hyperkinetic movements</td>
<td>Yes</td>
<td>Only at young age</td>
<td>&lt;1 min</td>
<td>Only at young age</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Norway IV-3 (Family D, McLellan et al., 2003)</td>
<td>α4-S248F</td>
<td>F</td>
<td>53</td>
<td>15</td>
<td>Strange feeling in head, hyperpnoea, raising of upper part of body, up on knees and elbows, repetitive turning of head</td>
<td>Yes</td>
<td>Only at young age</td>
<td>10–30 s</td>
<td>Only at young age</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Scotland IV-1 (Leniger et al., 2003)</td>
<td>α4-S248F</td>
<td>M</td>
<td>23</td>
<td>12</td>
<td>Sitting up, drumming of arms and legs on the bed and gasps for breath</td>
<td>Yes</td>
<td>Only at young age</td>
<td>5–20 s</td>
<td>Only at young age</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Scotland IV-2</td>
<td>α4-T265I</td>
<td>M</td>
<td>12</td>
<td>15</td>
<td>Irregular jerks of upper limbs, staring, falling off the bed</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany III-2 (Rozycka et al., 2003)</td>
<td>α4-S252L</td>
<td>M</td>
<td>22</td>
<td>9</td>
<td>Tonic stiffening of upper limbs, bipedalling of lower limbs, inconsistent talk</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland III-3 (Gambaradella et al., 2000)</td>
<td>β2-V287L</td>
<td>M</td>
<td>11</td>
<td>12</td>
<td>Sensation of being out of breath, tonic stiffening, inability to talk</td>
<td>Yes</td>
<td>Rare</td>
<td>10–40 s</td>
<td>No</td>
<td>Motor aphasia (1–2 min); hyperthermia after clusters of seizures</td>
<td>No</td>
</tr>
<tr>
<td>Italy III-3</td>
<td>β2-V287L</td>
<td>M</td>
<td>22</td>
<td>10–40 s</td>
<td>Indefinite feeling in head, then diffuse stiffening followed by truncal flexion and facial grimacing</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Italy III-4</td>
<td>β2-V287L</td>
<td>M</td>
<td>12</td>
<td>10–40 s</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No. of seizures per night</th>
<th>Around 10 (clusters)</th>
<th>Cluster of seizures</th>
<th>Long cluster of seizures (around 20)</th>
<th>4–5</th>
<th>20–30</th>
<th>10–20</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interictal EEG</td>
<td>Normal</td>
<td>Not done</td>
<td>Normal</td>
<td>Normal</td>
<td>Sparse bifrontal slow sharp waves, intermittent frontotemporal theta activity</td>
<td>Not done</td>
<td>Not localizing</td>
</tr>
<tr>
<td>Ictal EEG</td>
<td>Arousal with no definite change</td>
<td>Right focal rhythmic abnormalities in some recordings; equivocal in others</td>
<td>Not done</td>
<td>Sudden arousals with high voltage bilateral rhythmic delta waves with superimposed muscle artefact</td>
<td>Not done</td>
<td>Not localizing</td>
<td>Not done</td>
</tr>
<tr>
<td>Brain MRI</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Current medication</td>
<td>CBZ 800 mg/day and clonazepam 4 mg/day</td>
<td>CBZ 1200 mg/day and clonazepam in the evening</td>
<td>CBZ 400 mg/day</td>
<td>CBZ 800 mg/day</td>
<td>CBZ 600 mg/day</td>
<td>CBZ 600 mg/day and clobazam 10 mg/day, but no compliance</td>
<td>Normal</td>
</tr>
<tr>
<td>Response</td>
<td>Good response with decrease of seizure frequency (1 per month) and milder symptoms these last 15 years</td>
<td>Persistence of seizures; CBZ stopped the secondary generalizations</td>
<td>Persistence of seizures (1 or 2 nights per month; related to alcohol, sleep deprivation or CBZ not taken)</td>
<td>Persistence of rare seizures (1 or 2 nights with seizures every 2 weeks); poor control even with CBZ 1200 mg/day</td>
<td>Persistence of rare seizures (1 or 2 seizures (twice a month))</td>
<td>Persistence of weekly seizures; refusal of another treatment</td>
<td></td>
</tr>
<tr>
<td>Smoker</td>
<td>Never</td>
<td>Yes; stopped 1 year ago</td>
<td>Never</td>
<td>Never</td>
<td>Never</td>
<td>Never</td>
<td>Never</td>
</tr>
<tr>
<td>Occurrence of seizures before PET examination</td>
<td>No seizure the previous night</td>
<td>No clear seizure during the preceding nights (short awakenings not excluded)</td>
<td>No (after a seizure, wakes up and feel unwell)</td>
<td>No seizure the previous night (last seizures around 10 days before)</td>
<td>Several seizures the previous night</td>
<td>No major seizure the previous night (wakes up when major seizure)</td>
<td>No major seizure the previous night (wakes up when major seizure)</td>
</tr>
</tbody>
</table>

Patient numbers refer to the family trees in the original papers reporting the corresponding families. The Norwegian patients IV-6 and IV-3 were first cousins. The Scottish patients IV-1 and IV-2 were brothers, like the Italian patients III-3 and III-4.

M: male; F: female; CBZ: carbamazepine.
PET data processing
Parametric images
The data analyses were performed using two approaches: the first is a data-driven analysis based on volumes of interest (VOIs) drawn on the images. Although the VOI technique is a useful method, it only analyses selected areas; thus many brain regions may be left unexplored. The second approach, a voxel-based analysis using the statistical parametric mapping software (SPM2), is expected to overcome this limitation, and the relationship between the change in nAChR density ([18F]-F-A-85380) or in glucose metabolism ([18F]-FDG) and its anatomical basis can be investigated more accurately.

Both data analyses were performed on volume of distribution (Vd) parametric images based on the ratio of brain tissue to unchanged F-A-85380 plasma concentration at equilibrium.

Parametric images were created using Anatomist software (http://brainvisa.free.fr). For each frame collected during the last 30 min of the emission scan, the radioactivity in each voxel was divided by the value of individually metabolite-corrected [18F]-F-A-85380 in venous plasma at the same time, providing thus the Vd for each voxel.

VOI analysis
For all subjects, VOIs were drawn on individual MR T1 images using Anatomist software (http://brainvisa.free.fr). Cortical VOIs were outlined anatomically, following the grey matter ribbon. The identification of key sulci on individual MR images allowed for the anatomical delineation. To ensure a good reproducibility of the VOI placement, all VOIs were drawn by the same experienced physician.

Fourteen VOIs were delineated in 3D on MR T1 images, based on clearly identified anatomical structures: prefrontal (31.0 ± 4.6 ml), frontal (9.3 ± 1.1 ml), operculum (3.5 ± 0.5 ml), parietal (8.8 ± 0.5 ml), temporal (6.9 ± 1.2 ml), occipital (10.1 ± 1.7 ml) cortices, caudate nucleus (3.1 ± 0.8 ml), putamen (3.9 ± 0.8 ml), thalamus (5.3 ± 0.9 ml), mesencephalon (1.1 ± 0.1 ml), cerebellum (5.8 ± 1.4 ml), hippocampus (1.6 ± 0.3 ml), pons (1.4 ± 0.4 ml) and corpus callosum (1.6 ± 0.3 ml). The VOI termed ‘frontal cortex’ corresponded to a grey matter ribbon drawn from the central sulcus on the inferior and middle frontal gyri, and included dorsolateral prefrontal cortex, while the VOI termed ‘prefrontal cortex’ corresponded to the fronto-polar area of the frontal lobe.

For each VOI, tissue to plasma ratio (Vd) was obtained from the PET parametric images of each subject after co-registration with the corresponding MR images using a mutual information algorithm. In control subjects, the Vd calculated using the tissue to plasma ratios obtained in VOIs were compared with the Vd obtained from kinetic analysis using either a two-tissue compartmental analysis or a Logan graphical analysis as described in Gallezot et al. (2005). The Vd obtained in all VOIs in control subjects and patients were compared using a two-way analysis of variance (ANOVA) followed by post-hoc t-test using the Bonferroni correction (StatView, Abacus Concepts).

SPM analysis of PET images
SPM2 was applied to Vd parametric images to localize mean group differences in [18F]-F-A-85380 uptake between ADNFLE patients and controls on a voxel-by-voxel basis (Wellcome Department of Cognitive Neurology, London, UK; implemented on Matlab 7.2). Prior to statistical analysis, the images were spatially normalized into an appropriate template.

For [18F]-F-A-85380 study, PET scans and MRI of each subject were co-registered. PET images were then normalized into the MRI template (T1.mnc) from SPM2. A smoothing procedure using an isotropic Gaussian kernel of 8 mm in full-width at half maximum was then applied to remove high-frequency noise from the images and to take into account anatomical differences between subjects.

For the [18F]-FDG studies, five ADNFLE patients were compared with a group of 30 control subjects studied at our institution (mean age: 39 years, SD = 15). [18F]-FDG PET images were normalized into a PET-dedicated template. The normalized images were smoothed with a 12 mm Gaussian filter.

For both PET studies, voxel size was 2 × 2 × 2 mm. The SPM comparisons between the parametric images of the patients and the parametric images of the control subjects were performed using a parametric two-sample t-test. We evaluated the entire brain volume (>200,000 voxels). For each analysis a proportional voxel threshold of 0.8 and proportional scaling of the parametric images were used.

All indicated coordinates correspond to MNI (Montreal Neurological Institute) coordinates. When precise anatomical localization in the Co-planar Stereotaxic Atlas (Talairach and Tournoux, 1988) was needed, the MNI coordinates of the local maxima of each cluster were converted into Talairach coordinates using an affine transform.

Results
In vitro studies
Competitive interactions between unlabelled and radioactive epibatidine were studied first. The two mutations, a4-S248F and b2-V287L, did not affect the epibatidine affinity for human a4b2 nAChR (data not shown). Thus, identical experimental conditions can be applied in all the competition experiments and the same epibatidine affinity constant can be used for the binding curves. Unlabelled F-A-85380 was able to totally displace [3H]-epibatidine from wild-type and mutant human a4b2 receptors with nearly similar potency (see online Supplementary material, Fig. 1, left panel). The shape of the curves indicates a binding to a single site. The affinity constants (K_i) are reported in Table 2. The mutations a4-S248F or b2-V287L do not modify significantly the affinity of F-A-85380 since values are within the 95% confidence interval (CI) of the measurements. Identical results were obtained whether the transfection simulates a ‘heterozygous’ or a ‘homozygous’ profile (data not shown).

Saturation experiments were carried out using the radiotracer [18F]-F-A-85380 itself (see online Supplementary material, Fig. 1, right panel). These experiments allowed direct measurement of the affinity constant (K_d) of F-A-85380 for the receptors. K_d values, reported in Table 2, are very
close for the wild-type and both mutated receptors, confirming that mutations \( \alpha_4\)-S248F or \( \beta_2\)-V287L do not modify significantly the affinity of F-A-85380.

Carbamazepine (50 \( \mu \)M, approximately the concentration present in the serum of patients treated for epilepsy) did not interfere with the labelled epibatidine and did not modify the F-A-85380 binding either to the wild-type or to the mutant receptors (data not shown).

**In vivo studies**

**[\(^{18}\)F]-F-A-85380 VOI analysis**

In the seven control subjects, the highest cerebral concentration of the ligand was in the thalamus. High to intermediate levels were observed in the mesencephalon, pons, putamen, caudate nucleus, cerebellum and cortices. The lowest concentration was observed in corpus callosum and occipital cortex. In the eight ADNFLE patients, the distribution of the concentration of ligand had a different pattern: there was a clear increase of the radiotracer uptake in the cerebellum, mesencephalon and pons.

Five of our control subjects belonged to the group of healthy volunteers reported by Gallezot et al. (2005). These subjects underwent a long PET protocol allowing kinetic analysis using both a two-tissue compartmental analysis and a Logan graphical analysis. In these control subjects, the comparison between Vd calculated by using this ratio did reflect the receptor concentration (Gallezot et al., 2005).

The individual parametric images in the patients confirmed the increased fixation in brainstem and cerebellum (e.g. shown in Fig. 1). The comparison of Vd values (Bonferroni corrected Student’s \( t \)-test) in the different VOIs showed a statistically significant increase in the cerebellum, pons and mesencephalon (21%, \( P = 0.0078 \); 18%, \( P = 0.047 \) and 12%, \( P = 0.035 \), respectively) in the group of patients (Fig. 2).

**Hyperfixation of [\(^{18}\)F]-F-A-85380 detected by SPM analysis**

SPM2 was used to compare the voxel values obtained in patients and controls. Increased uptake in the group of patients was tested at uncorrected \( P \)-values < 0.001. Among the regions with a significant increased uptake, only those

<table>
<thead>
<tr>
<th>Table 2 F-A-85380 affinity constants on wild-type and mutant human ( \alpha_4\beta_2 ) receptors</th>
</tr>
</thead>
<tbody>
<tr>
<td>K_D (pM) (mean ± SD)</td>
</tr>
<tr>
<td>( \alpha_4\beta_2 )</td>
</tr>
<tr>
<td>( \alpha_4\alpha_4^* \beta_2 )</td>
</tr>
<tr>
<td>( \alpha_4\beta_2^* \beta_2 )</td>
</tr>
</tbody>
</table>

Affinity constants determined by saturation using [\(^{18}\)F]-F-A-85380 (K_D) or by competition using [\(^{3}\)H]-epibatidine (K_i). The star (*) indicates a mutated subunit, S248F on \( \alpha_4 \) and V287L on \( \beta_2 \).
Mesencephalon/C0
Left cerebellum
Right cerebellum
Cerebellar vermis

Table 3 SPM analysis of [18F]-F-A-85380 hyperfixation in ADNFLE patients

<table>
<thead>
<tr>
<th>Location</th>
<th>Local maxima MNI coordinates</th>
<th>Z-score (voxel level)</th>
<th>Cluster size (voxels)</th>
<th>P_corrected (cluster level)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>x (mm) y (mm) z (mm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mesencephalon</td>
<td>−2 −22 0</td>
<td>4.63</td>
<td>699</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Lefc cerebellum</td>
<td>−16 −80 −52</td>
<td>4.21</td>
<td>1256</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Right cerebellum</td>
<td>22 −76 −60</td>
<td>4.15</td>
<td>392</td>
<td>0.003</td>
</tr>
<tr>
<td>Cerebellar vermis</td>
<td>0 −68 −12</td>
<td>3.94</td>
<td>325</td>
<td>0.007</td>
</tr>
</tbody>
</table>

Patients n = 8; controls n = 7; Puncorrected < 0.001. Regions with a significant increase (Pcorrected at cluster level < 0.05) are shown. For each cluster, at most three local maxima, separated by at least 8 mm, are given.

In a second step, SPM analysis was applied to the data of the subgroup of patients with an α4 mutation (n = 6) and of the small subgroup of patients with a β2 mutation (n = 2). The α4 subgroup showed the same pattern of increased fixation as the whole group of ADNFLE patients, but with a significant increase after correction for cluster size in the mesencephalon (borderline significance at the voxel level for the local maximum located in the lower part of the mesencephalon, at 2 −16 −14, with a P_{FDR-corrected} = 0.050). The β2 subgroup showed a significant increase of tracer concentration at the cluster level in cerebellar hemispheres (Pcorrected < 0.0001). In addition, within a small non-significant cluster appearing in the thalami, there were two local maxima (MNI coordinates: −4 −14 12 and 4 −12 12) with a P_{FDR-corrected} close to significance (P = 0.056), located in the mediodorsal thalamic nucleus, according to the Talairach atlas. Interestingly one of the patients with an α4 mutation (Patient IV-6, Norway) also showed an identical spot (MNI coordinates: −2 −14 10) with a statistically significant P at voxel level after correction for FDR, P_{FDR-corrected} = 0.035.

Hypofixation of [18F]-F-A-85380 detected by SPM analysis

In the same way, SPM2 was used to localize any significant cluster of F-A-85380 decreased binding in the group of patients at a P_{uncorrected} < 0.001 and a P_{corrected} for the cluster level < 0.05. The cluster size threshold allowing to select regions with significant P-values was 200 voxels (1.6 cm³).

A cluster of 615 voxels was observed in the right prefrontal area (P_{corrected} for the cluster < 0.001). The voxel with the highest Z-score was located in the superior frontal gyrus at the border between Brodmann’s areas 9 and 10 (MNI coordinates: 28 52 26; Z = 4.53; P_{FDR-corrected} = 0.081) (Table 4 and Fig. 4A and B). Other significant clusters were: in the right caudate nucleus (279 voxels; P_{corrected} = 0.014; MNI coordinates of the local maximum: 18 24 0; Z = 3.90) and in the right rolandic opercular area (215 voxels; P_{corrected} = 0.041; MNI coordinates of the local maximum: 25 36 −4 −2; Z = 3.86).

Even at the level of individual patients, the decrease in tracer concentration was statistically significant in the right prefrontal region in seven patients (dorsolateral in three,
orbitofrontal in three and both areas in one patient). A decrease was also observed in the rolandic opercular region (right in seven and left in one) in the eight patients, at a significant level for three patients.

There was no difference between the patients with an α4 mutation and those with a β2 mutation.

**SPM analysis of [18F]-FDG PET**

FDG PET was carried out in five ADNFLE patients. The SPM comparison was done with a group of 30 healthy volunteers. ADNFLE patients did not show any hyperfixation when compared to controls. A decrease of FDG fixation was observed in the right and left anterior orbitofrontal cortex, with a right predominance, in the right and left opercular regions, and in the right supramarginal gyrus (inferior parietal lobule) in patients (Table 5). However, for all regions, the P-values after correction for cluster size were not statistically significant.

The region of the [18F]-F-A-85380 hypofixation and the region of glucose hypometabolism in the right prefrontal cortex were close to each other. The glucose hypometabolism was slightly below the region of [18F]-F-A-85380 hypofixation (Fig. 4A and D). In addition, a concomitant decrease of [18F]-F-A-85380 fixation and glucose metabolism was observed in almost identical parts of the right rolandic opercular region (Fig. 4C and F).

**Discussion**

The comparison of [18F]-F-A-85380 binding between a group of eight non-smoking ADNFLE patients, in whom a mutation was identified, and a group of control subjects showed clear regional differences. First, the comparison of the parametric PET images between the two groups showed statistically significant increases of tracer fixation in the cerebellum, pons and mesencephalon. The other VOIs showed no significant changes. Second, SPM analysis allowed a more discriminative spatial comparison of the entire brain. A statistically significant increase in nAChR density was observed in the group of ADNFLE patients in a region including the mesencephalon and an adjacent part of the diencephalon (superior area of the epithalamus), and in the cerebellum. Thus, both methods could identify statistically significant changes in mesencephalon and cerebellum. The increase in nAChR density in the brainstem is an exciting discovery which may open new vistas on the pathogenesis of ADNFLE. Moreover, SPM analysis allowed to identify a statistically significant decrease in nAChR density in the right prefrontal area in the group of ADNFLE patients. So far, it has been hard to understand why mutations in receptors that are present in the entire brain result in the clinical picture of a focal epilepsy. This finding of regional decrease in nAChR density may in part explain this phenomenon. The location of the decrease in the prefrontal cortex appears compatible with a frontal lobe epilepsy.

**Relevance of the differences observed between ADNFLE patients and control subjects**

The nAChR distribution in our group of control subjects agreed with a previous study in non-smoking healthy volunteers using the same tracer (Kimes et al., 2003).
Table 4 SPM analysis of $[^{18}F]$-F-A-85380 hypofixation in ADNFLE patients

<table>
<thead>
<tr>
<th>Location</th>
<th>Local maxima MNI coordinates</th>
<th>Z-score (voxel level)</th>
<th>Cluster size (voxels)</th>
<th>$P_{corrected}$ (cluster level)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$x$ (mm) $y$ (mm) $z$ (mm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right prefrontal cortex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>28 52 26</td>
<td>4.53</td>
<td>615</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td></td>
<td>26 66 12</td>
<td>4.26</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>18 70 6</td>
<td>4.26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right caudate</td>
<td>18 24 0</td>
<td>3.90</td>
<td>279</td>
<td>0.014</td>
</tr>
<tr>
<td></td>
<td>26 12 18</td>
<td>3.85</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>26 24 10</td>
<td>3.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right opercular area</td>
<td>56 $-4$ $-2$ $3.86$</td>
<td>215</td>
<td>0.041</td>
<td></td>
</tr>
<tr>
<td></td>
<td>56 $-10$ $-2$ $3.81$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>56 $-14$ 18 $3.81$</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patients $n = 8$; controls $n = 7$; $P_{uncorrected} < 0.001$. Regions with a significant reduction ($P_{corrected}$ at cluster level < 0.05) are shown. For each cluster, at most three local maxima, separated by at least 8 mm, are given.

Fig. 4 SPM analysis of $[^{18}F]$-F-A-85380 and of $[^{18}F]$-FDG PET hypofixation in ADNFLE patients. (A–C) correspond to the $[^{18}F]$-F-A-85380 analysis (patients $n = 8$; controls $n = 7$; $P_{uncorrected} < 0.001$, $P_{corrected}$ at cluster level < 0.05). (D–F) correspond to the $[^{18}F]$-FDG analysis (patients $n = 5$; controls $n = 30$; $P_{uncorrected} < 0.001$). Z-values of statistical significance are represented by the colour bar on the right. The figure focuses on the prefrontal region (B and E) with the region of glucose hypometabolism (E) being beneath the region of F-A-85380 hypofixation (B). The right side is on the right on the coronal MRI images. Parts C and F show that the regions of glucose hypometabolism and of F-A-85380 hypofixation in the right opercular cortex are superimposable.
distribution was also consistent with data obtained in vitro, except for the hippocampus which in vivo has a slightly higher binding than the neocortex (Marutle et al., 1998).

Before interpreting the alterations of nAChR binding observed in patients, we excluded a bias related to a modification of affinity of the tracer for the nAChRs by either the mutation or the antiepileptic drug carbamazepine.

The affinity of F-A-85380 was determined in vitro by two different approaches: indirect affinity measurement ($K_i$) by competition of F-A-85380 with $[^3]H$epibatidine and direct measurement ($K_D$) by saturation experiments using the radiotracer $[^18F]$-F-A-85380 itself. Our results showed that, despite the slight difference observed in the $K_i$ values, the affinity ($K_D$) of the radiotracer $[^18F]$-F-A-85380 was similar for wild-type $\alpha 4\beta 2$ nAChRs and for the mutant $\alpha 4\beta 2$ nAChRs. In the literature, affinity of radioligands for mutant nAChRs was found unchanged (Rodrigues–Pinguet et al., 2003), slightly increased (Fonck et al., 2005) or decreased (Kuryatov et al., 2005).

In addition, oral carbamazepine does not modify the F-A-85380 binding to wild-type or to mutant nAChRs. Indeed, two of our patients who did not take carbamazepine had the same Vd values as patients taking carbamazepine. Also in vitro, carbamazepine at a concentration in the therapeutic range did not change the affinity of F-A-85380 for wild-type and mutant $\alpha 4\beta 2$ nAChRs.

**nAChR subtype-specificity of $[^18F]$-F-A-85380**
The increase of $[^18F]$-F-A-85380 Vd reflects an increased number of heteromeric nAChRs as this tracer has very low affinity for the homomeric $\alpha 7$ subtypes (Deuther–Conrad et al., 2004). Among the heteromeric nAChRs, $[^18F]$-F-A-85380 exhibits a clear selectivity for $\alpha 4\beta 2$ over $\alpha 3\beta 4$ receptors ($K_i$ ratio 1200) (Deuther–Conrad et al., 2004). Affinity of our tracer for the other less abundant subtypes ($\alpha 3\beta 2$, $\alpha 2\beta 2$ and $\alpha 6\beta 2$) remains to be established.

**Which mechanisms may give rise to a regional increase in nAChR density?**
The mechanisms behind the regional increase in nAChRs in ADNFLE patients are yet unknown. A first possibility is that the mutant nAChRs may have caused regional structural CNS developmental abnormalities. The involvement of the nAChRs in the development of the CNS has been extensively described (Court et al., 1995; Zoli et al., 1995; Adams, 2003; Torrao et al., 2003). The mutant receptors may possibly have allowed the persistence of an excessive number of synapses in the epithalamus, IPN and cerebellum.

A second possibility is a regional upregulation of receptors. In rat, nicotine selectively upregulates $\alpha 4\beta 2$ nAChRs, with a different sensitivity to upregulation in different brain regions (Nguyen et al., 2003). Even choline upregulates the nAChRs (Sallette et al., 2005). In HEK cells expressing the $\alpha 4$-S247F mutant, ACh produced an upregulation of mutant nAChRs (Kuryatov et al., 2005). We postulate that a regional upregulation in the habenulointerpeduncular region in ADNFLE patients could be related to the richness in sites of ACh release and in heteromeric nAChRs in this region (Sastry, 1978; Tribollet et al., 2004; Zoli et al., 1998) and to the hypersensitivity of the ADNFLE mutant nAChRs to ACh.

**Could the nAChR density changes be involved in the pathogenesis of ADNFLE?**
The regional increases in nAChR density observed in ADNFLE patients do not seem to be caused by epileptic seizures, since the majority of the patients did not suffer from recent seizures at the time of examination (see Table 1). Larger studies in the future with different populations of patients with epilepsy will determine whether the changes in regional density are specific for the ADNFLE syndrome. If we suppose that these changes indeed are specific, three main questions emerge. Are the regional increases in nAChR density responsible for the sleep-related expression of the disorder? Are these modifications responsible for epileptic seizures? And finally, are they responsible for the particular hypermotor semiology of the seizures?

**Are the nAChR density modifications responsible for the sleep-related occurrence of the attacks?**
ADNFLE seizures mainly occur during stage 2 of non-rapid eye movement (non-REM) sleep. This stage is characterized by the presence of sleep spindles, which are transient

### Table 5 SPM analysis of $[^18F]$-FDG PET hypofixation in ADNFLE patients

<table>
<thead>
<tr>
<th>Location</th>
<th>Local maxima MNI coordinates</th>
<th>Z-score (voxel level)</th>
<th>Cluster size (voxels)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right parietal area</td>
<td>44</td>
<td>32</td>
<td>4.32</td>
</tr>
<tr>
<td>Right prefrontal cortex</td>
<td>34</td>
<td>48</td>
<td>3.89</td>
</tr>
<tr>
<td>Left prefrontal cortex</td>
<td>30</td>
<td>4</td>
<td>3.52</td>
</tr>
<tr>
<td>Right opercular area</td>
<td>66</td>
<td>20</td>
<td>3.40</td>
</tr>
<tr>
<td>Left opercular area</td>
<td>64</td>
<td>8</td>
<td>3.38</td>
</tr>
</tbody>
</table>

Patients $n = 5$; controls $n = 30$; $P_{uncorrected} < 0.001$. 
physiological rhythmic oscillations, with frequencies between 11 and 15 Hz, grouped in sequences that last 0.5–3 s and recur every 3–10 s. They originate in the thalamus and represent thalamocortical oscillations. ADNFLE seizures often seem to arise from sleep spindles (Picard and Scheffer, 2005).

The finding of an increased number of nAChRs in the regions of the epithalamus (medial habenular area) and of the IPN seems particularly interesting in the context of a sleep disorder. These structures are part of the limbic system outflow into the brainstem (Nauta, 1958). They are linked by the fasciculus retroflexus, a cholinergic projection from the medial habenula to the IPN. Interestingly, this tract undergoes an extraordinarily selective degeneration under continuous nicotine exposure in rats (Carlson et al., 2000). The IPN projects to the ventral tegmental area and to reticular and tegmental brainstem nuclei, particularly the laterodorsal tegmental nucleus (LDT), which is part of the ascending cholinergic pathway from the LDT to the IPN. In ADNFLE, the hyperfunctioning mesopontine cholinergic pathway would chronically overactivate the LDT and consequently the mediodorsal thalamic nucleus. At the time of arousals, the release of ACh in the thalamus, a tonic activation (desynchronized awake state) is triggered and maintained in the thalamocortical system. In vivo electrical stimulation of these nuclei or local application of ACh on thalamocortical neurons induces a depolarization of thalamocortical neurons, first mediated by nicotinic receptors, which interrupts the sleep spindle oscillations (Curro Dossi et al., 1991; Lee and McCormick, 1997).

In ADNFLE, the hyperfunctioning mesopontine cholinergic pathway would chronically overactivate the LDT and consequently the mediodorsal thalamic nucleus. At the time of arousals, the release of ACh in a sensitized mediodorsal thalamic nucleus could prevent the normal arousal-induced interruption of the sleep spindle oscillations and transform them into pathological thalamocortical oscillations, triggering epileptic seizures. Such a transformation of the sleep spindles into epileptic discharges was proposed many years ago in absence epilepsy based on animal models, e.g. the feline generalized penicillin epilepsy (Gloor et al., 1979; Gloor and Fariello, 1988) and the genetic model genetic absence epilepsy rats from Strasbourg (GAERS) (Avanzini et al., 2000), but never in a focal epilepsy.

Could the regional modifications in nAChR density be responsible for the particular hypermotor expression of the seizures?

In ADNFLE, the transformation of the thalamocortical sleep oscillations into pathological oscillations would affect the regions of projection of the mediodorsal thalamic nucleus, namely the orbital and dorsolateral prefrontal cortex, the anterior cingulate cortex and the anterior part of the insula (Behrens et al., 2003; Giguere and Goldman-Rakic, 1988). Interestingly, the frontal sleep spindles, from which the ADNFLE seizures seem to arise, are maximal in cortical regions (Brodmann’s areas 9 and 10) which are reciprocally connected to the mediodorsal thalamic nucleus (Anderer et al., 2001).

The decrease in nAChR density and in glucose metabolism observed in the right prefrontal cortex in the group of patients may reflect a neuronal loss, either affecting the prefrontal thalamocortical neurons (presynaptic nAChRs) which undergo an overactivation, or affecting prefrontal cortical neurons (postsynaptic nAChRs) in relation to the epileptic seizures. According to our results, the right Rolandic opercular region is involved in the epileptogenic thalamocortical network.

Could the regional modifications in nAChR density be responsible for the particular hypermotor expression of the seizures?
ADNFLE seizures present with intense agitation (frantic and/or dystonic movements) evoking an innate stereotyped motor behaviour of extrapyramidal character. Its precise anatomical origin is not fully understood. The seizures could trigger the release from cortical inhibitory influences of brainstem 'central pattern generators' which control innate motor behaviours essential for survival (Tassinari et al., 2003). Such a disruption of an inhibitory connection from prefrontal regions to the amygdala was recently suggested to account for the release of archaic behaviour suggestive of intense fear in patients with frontal lobe seizures (Bartolomei et al., 2005). In our patients, the prefrontal regions showing a decrease in nAChR density and in glucose metabolism could be implicated in the ictal archaic motor behaviour via a disinhibition of subcortical structures, e.g. at a limbic or extrapyramidal level.

In summary our work shows significant regional changes in brain nAChR density in ADNFLE patients. These changes point towards an overactivated cholinergic pathway ascending from the brainstem. Complementary studies in humans and in animal models are in progress and may help to support the implication of the cholinergic projections from the brainstem to the thalamus in ADNFLE pathogenesis.

Supplementary material
Supplementary data are available at Brain Online.

Acknowledgements
This work was supported by the Swiss National Foundation no. 3100A0-104190/1, the DRRRC-Assistance Publique des Hôpitaux de Paris, and Sanofi-Aventis. We thank Prof. C. Marescaux, Dr J.-B. Poline and Dr Alexis Roche for helpful discussions and Dr B. Zifkin for critical reading of the manuscript.

References


Lee KH, McCormick DA. Modulation of spindles oscillations by acetylcholine, cholecystokinin and 15,3R-ACPD in the ferret lateral geniculate and perigeniculate nuclei in vitro. Neuroscience 1997; 77: 335–50.


